Hypertrophic scars occur due to the deposition of excessive amounts of collagen during the healing process of cuts, burns, and body piercings. Hypertrophic scars become raised, swollen and reddened during wound healing causing them to stand out from the surrounding skin. These scars can itch and be painful, and are uniform. Hypertrophic scar may contain nerves and blood vessels and these scars are often found on the breastbone, ears, and shoulders. Positive Pre-clinical and clinical trial results of the drugs being developed for the treatment of hypertrophic scars, and funding from the healthcare organizations are the factors, driving the growth of the hypertrophic scars pipeline. RXi Pharmaceuticals Corporation is in the process of developing RXI-109 as a connective tissue growth factor inhibitor for the treatment of hypertrophic scars.
HYPERTROPHIC SCARS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
As of November 2017, hypertrophic scars therapeutics pipeline comprises of nine drug candidates in different stages of development.
Some of the players developing drugs for the treatment of hypertrophic scars include RXi Pharmaceuticals Corporation, Sirnaomics, Inc., ScarX Therapeutics, Inc., and Scarless Laboratories, Inc.